Back to results

CompletedPhase 2

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

NCT02708186

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

US120

Birmingham, Alabama, United States

+22 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2016-03
Enrollment: 34 participants
Sponsor: Axovant Sciences Ltd.
Purpose: treatment

Locations (23)

US120Birmingham, Alabama, United States
US164Phoenix, Arizona, United States
US145Sun City, Arizona, United States
US143Little Rock, Arkansas, United States
US122Englewood, Colorado, United States
US180Maitland, Florida, United States
US154Ocala, Florida, United States
US113Orlando, Florida, United States
US152Ormond Beach, Florida, United States
US153Tampa, Florida, United States
US163Atlanta, Georgia, United States
US107Indianapolis, Indiana, United States
US132Lenexa, Kansas, United States
US129Lincoln, Nebraska, United States
US101Chapel Hill, North Carolina, United States
US159New Bern, North Carolina, United States
US147Fargo, North Dakota, United States
US111Cincinnati, Ohio, United States
US104Cleveland, Ohio, United States
US105Columbus, Ohio, United States
US173Lincoln, Rhode Island, United States
US128Memphis, Tennessee, United States
US131San Antonio, Texas, United States

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) — TrialFind